PRHSX vs. FSMEX

In the year-to-date period, PRHSX achieves a 6.30% return, which is significantly lower than FSMEX's 6.99% return. Over the past 10 years, PRHSX has underperformed FSMEX with an annualized return of 1.78%, while FSMEX has yielded a comparatively higher 6.63% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

PRHSX has a 0.80% expense ratio, which is higher than FSMEX's 0.68% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for T. Rowe Price Health Sciences Fund (PRHSX) and Fidelity Select Medical Technology and Devices Portfolio (FSMEX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PRHSX Sharpe Ratio is -0.26, which is lower than the FSMEX Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of PRHSX and FSMEX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

PRHSX's dividend yield for the trailing twelve months is around 0.01%, while FSMEX has not paid dividends to shareholders.

The maximum PRHSX drawdown since its inception was -47.79%, which is greater than FSMEX's maximum drawdown of -43.45%. Use the drawdown chart below to compare losses from any high point for PRHSX and FSMEX. For additional features, visit the drawdowns tool.

T. Rowe Price Health Sciences Fund (PRHSX) and Fidelity Select Medical Technology and Devices Portfolio (FSMEX) have volatilities of 4.40% and 4.32%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.